Lilah Olsher

About the Author Lilah Olsher

Lilah Olsher graduated from Temple University with a BA in Marketing. Ms. Olsher is the Head of Contributors for Smarter Analyst.

Oppenheimer Remains Sidelined on BlackBerry Ltd Ahead of F1Q16 Results

Oppenheimer analyst Andrew Uerkwitz weighed in with some insights on BlackBerry Ltd (NASDAQ:BBRY) ahead of its first quarter fiscal year 2016 results which will …

Apple Inc. (AAPL) Removes Original iPad Mini From its Inventory

It seems as though Apple Inc. (NASDAQ:AAPL) has developed a concern for its customers eyes, as the company did away with its 1st …

Oppenheimer Initiates Outperform on Vonage Holdings Corp (VG); Sees 25% Upside For The Stock

Oppenheimer analyst Timothy Horan initiated coverage on shares of  Vonage Holdings Corp. (NYSE:VG) with an Outperform rating and a price target of $6.

Maxim Group Defends Teva Pharmaceutical Industries Ltd (ADR) Despite Patent Invalidation for Copaxone

Maxim Group analyst Jason Kolbert weighed in today with some commentary on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) after a U.S.

Brean Capital Reiterates Positive Outlook on Zogenix, Inc. Ahead of Reverse Stock Split

Brean Capital analyst Difei Yang weighed in today with his prediction Zogenix, Inc. (NASDAQ:ZGNX) ahead of the reverse stock split that will be implemented on …

Here’s Why Oppenheimer Remains Optimistic on Bank of America Corp

Oppenheimer analyst Chris Kotowski weighed in with his opinions on Bank of America Corp (NYSE:BAC) as a follow up to the his report on the company published last …

Cantor Maintains Buy on Oracle Corporation (ORCL) Following Above Expectations Cloud Performance

In a research report issued today, Cantor analyst Brian White weighed in with some insights on Oracle Corporation (NYSE:ORCL) after looking at the company’s cloud …

Apple Inc. (AAPL) Security Investigation Unearths Data Compromising Bugs

Much to the dismay of Apple Inc. (NASDAQ:AAPL) users everywhere, three weaknesses in cross-app resource sharing were discovered by a research team from …

Roth Capital Reiterates Buy on CTI BioPharma Corp Following New PRO Data Released for pacritinib

Roth Capital analyst Debjit Chattopadhyay weighed in with a few of his opinions on CTI BioPharma Corp (NASDAQ:CTIC) after the company released new patient-reported outcome (PRO) …

Piper Jaffray Remains Sidelined on Regeneron Pharmaceuticals Inc Ahead of Decision to Opt into AVA-101 Development

In a research report issued today, Piper Jaffray analyst Edward Tenthoff weighed in with a few insights on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) following Avalanche’s …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts